DOACs Versus Warfarin for VTE in Sickle Cell Disease: Bayesian Pooling
This Bayesian meta-analysis of four retrospective cohorts gives anticoagulation pharmacists the first probabilistic comparison of direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) for venous thromboembolism (VTE) in adults with sickle cell disease (SCD), with a bleeding signal that is promising but heavily confounded.
📅 Journal publication: Oct 2026(online Oct 14, 2026)·Last updated: Nov 16, 2026
direct oral anticoagulantsDOACsvitamin K antagonistswarfarinapixabanrivaroxabanedoxabandabigatransickle cell diseasevenous thromboembolismmajor bleedingBayesian meta-analysisobservational studiesanticoagulationAnticoagulation / Hematology
Background Information
DOACs could offer safer VTE management in sickle cell patients.
Choosing the right anticoagulant for venous thromboembolism (VTE) in sickle cell disease (SCD) is crucial for safety and efficacy. Direct oral anticoagulants (DOACs) reduce major bleeding (OR 0.25; 95% CrI, 0.07-0.80) but show similar efficacy to vitamin K antagonists (VKAs) for VTE. DOACs may offer a safer alternative to VKAs in SCD patients with VTE, but results are from retrospective studies, needing further research. In SCD with VTE, DOACs may lower major bleeding risks compared to VKAs.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Le Jeune S, Mahé I, Morabito A, Datchanamourty J, Happe F, Versini E, Affo L, Frere C
Citation:Le Jeune S, Mahé I, Morabito A, et al. Direct oral anticoagulants versus vitamin K antagonists for the treatment of venous thromboembolism in adults with sickle cell disease: a Bayesian meta-analysis. Research and practice in thrombosis and haemostasis. 2026;10(7):107015. doi:10.1016/j.rpth.2026.107015